Gene interactions and pathways from curated databases and text-mining

◀ Back to MAPK13

MAP2K6 — MAPK13

Pathways - manually collected, often from reviews:

  • OpenBEL Selventa BEL large corpus: MAPK13 → MAP2K6 (increases, MAP2K6 Activity, MAPK13 Activity) Goedert et al., EMBO J 1997*
    Evidence: SAPK4 was activated in vitro by SKK3 (also called MKK6) MKK6 was found to be the major upstream activator of SAPK4
  • OpenBEL Selventa BEL large corpus: MAPK13 → MAP2K6 (increases, MAP2K6 Activity, MAPK13 Activity) Zhao et al., Mol Cell Biol 1999
    Evidence: Following the initial description of p38 (p38a), three additional isoforms of this MAP kinase group have been cloned and characterized: p38b (18), p38g (also termed ERK6 or SAPK3) (22, 24, 30), and p38d (also termed SAPK4) (4, 17, 41). Two MAP kinase kinases (MKK), MKK3 and MKK6, are the upstream activators of the p38 group MAP kinases (6, 12, 14, 37).
  • KEGG Osteoclast differentiation: MAP2K6 → MAPK11/MAPK12/MAPK13/MAPK14 (protein-protein, activation)
  • KEGG Toll-like receptor signaling pathway: MAP2K3/MAP2K6 → MAPK11/MAPK12/MAPK13/MAPK14 (protein-protein, phosphorylation)
  • KEGG Fc epsilon RI signaling pathway: MAP2K3/MAP2K6 → MAPK11/MAPK12/MAPK13/MAPK14 (protein-protein, activation)
  • KEGG GnRH signaling pathway: MAP2K3/MAP2K6 → MAPK11/MAPK12/MAPK13/MAPK14 (protein-protein, activation)
  • KEGG Amyotrophic lateral sclerosis (ALS): MAP2K6 → MAPK11/MAPK12/MAPK13/MAPK14 (protein-protein, activation)
  • KEGG MAPK signaling pathway: MAP2K6 → MAPK11/MAPK12/MAPK13/MAPK14 (protein-protein, phosphorylation)
  • KEGG Toxoplasmosis: MAP2K3/MAP2K6 → MAPK11/MAPK12/MAPK13/MAPK14 (protein-protein, activation)
  • KEGG Influenza A: MAP2K3/MAP2K6 → MAPK11/MAPK12/MAPK13/MAPK14 (protein-protein, activation)

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

Text-mined interactions from Literome

Martel-Pelletier et al., Arthritis Rheum 1999 (Osteoarthritis) : Within minutes, IL-17 induced the phosphorylation of mitogen activated protein kinase kinase-1/2 ( MEK-1/2 ), -3/6 ( MKK-3/6 ), p44/42, p38, and inhibitor of nuclear factor kappaB ( I kappaB)-alpha, as well as the activation of mitogen activated protein kinase activated protein kinase-1 and -2 ( MAPKAPK-1 and -2 )
Tu et al., J Biomed Sci 2001 (Carcinoma, Hepatocellular) : On the other hand, PD98059, a specific inhibitor of mitogen activated protein kinase kinase , blocks TPA induced MAPK activation but has no effect on TPA induced tyrosine phosphorylation
Huang et al., Biochem Biophys Res Commun 2003 : MAP3Ks are components of a three tiered protein kinase pathway in which a MAP3K phosphorylates and activates a mitogen activated protein kinase kinase ( MAP2K ), which in turn activates a mitogen activated protein kinase ( MAPK )
Wu et al., Free Radic Biol Med 2010 (Drug-Induced Liver Injury) : This was followed by activation of MKK3/MKK6 and MKK4/MKK7 at 4-8 or 12h and then JNK/p38 MAPK at 8 to 12h
Lee et al., Nat Med 2011 (Obesity) : Further, we show that activation of p38 MAPK by expression of constitutively active MAP kinase kinase 6 ( MKK6Glu ) greatly enhances nuclear translocation of Xbp1s, reduces endoplasmic reticulum stress and establishes euglycemia in severely obese and diabetic mice
Huwiler et al., Br J Pharmacol 1994 : 2. Both nucleotides stimulate phosphorylation and activation of mitogen activated protein kinase and a biphasic phosphorylation of the up-stream mitogen activated protein kinase kinase
Daum et al., FEBS Lett 1998 : Pervanadate inhibits mitogen activated protein kinase kinase-1 in a p38MAPK dependent manner